Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Hepalatide in Healthy Volunteers
NCT03023787Phase 1Completed
- Sponsor
- Shanghai Hepu Pharmaceutical
- Start
- Aug 2016
- Primary completion
- Dec 2016
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hepalatide in hepatitis B (HBV) (4 arms), sponsored by Shanghai Hepu Pharmaceutical. Primary endpoint: Treatment-related adverse events at 6 months. Started Aug 2016; status: completed.
02
Drugs
hepalatide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03023787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03023787.